Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Inactivated EV71 Vaccine (Envacgen) in Infants and Children
NCT03865238Phase 3Completed
- Sponsor
- Medigen Biotechnology
- Start
- Apr 2019
- Primary completion
- Apr 2021
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in enterovirus 71 infection comparing EV71vac with Placebo (2 arms). Primary endpoint: Number of Laboratory Confirmed EV71-Associated Disease at 14 months. Started Apr 2019; status: completed.
02
Drugs
EV71vac
03
Conditions
enterovirus 71 infection
Beyond the preview
Go deeper on NCT03865238.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03865238.